Annual FCF
-$97.06 M
-$20.49 M-26.76%
December 31, 2024
Summary
- As of March 12, 2025, URGN annual free cash flow is -$97.06 million, with the most recent change of -$20.49 million (-26.76%) on December 31, 2024.
- During the last 3 years, URGN annual FCF has fallen by -$11.42 million (-13.33%).
- URGN annual FCF is now -2877.93% below its all-time high of $3.49 million, reached on December 31, 2016.
Performance
URGN Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$13.73 M
+$14.03 M+50.53%
December 1, 2024
Summary
- As of March 12, 2025, URGN quarterly free cash flow is -$13.73 million, with the most recent change of +$14.03 million (+50.53%) on December 1, 2024.
- Over the past year, URGN quarterly FCF has increased by +$14.03 million (+50.53%).
- URGN quarterly FCF is now -632.95% below its all-time high of $2.58 million, reached on September 30, 2017.
Performance
URGN Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$97.06 M
-$682.00 K-0.71%
December 1, 2024
Summary
- As of March 12, 2025, URGN TTM free cash flow is -$97.06 million, with the most recent change of -$682.00 thousand (-0.71%) on December 1, 2024.
- Over the past year, URGN TTM FCF has dropped by -$682.00 thousand (-0.71%).
- URGN TTM FCF is now -3338.22% below its all-time high of -$2.82 million, reached on March 31, 2017.
Performance
URGN TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
URGN Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -26.8% | +50.5% | -0.7% |
| 3 y3 years | -13.3% | +32.3% | -13.3% |
| 5 y5 years | -36.0% | +47.6% | -36.0% |
URGN Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -26.8% | at low | -5.2% | +56.7% | -26.8% | at low |
| 5 y | 5-year | -36.0% | +9.4% | -5.2% | +61.6% | -36.0% | +13.2% |
| alltime | all time | -2877.9% | +9.4% | -633.0% | +61.6% | -3338.2% | +13.2% |
UroGen Pharma Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$97.06 M(+26.8%) | - | - |
| Dec 2024 | - | -$13.73 M(-50.5%) | -$97.06 M(+0.7%) |
| Sep 2024 | - | -$27.76 M(+16.5%) | -$96.38 M(+12.0%) |
| Jun 2024 | - | -$23.83 M(-24.9%) | -$86.02 M(+4.3%) |
| Mar 2024 | - | -$31.73 M(+143.1%) | -$82.47 M(+7.7%) |
| Dec 2023 | -$76.57 M(-12.8%) | -$13.05 M(-25.0%) | -$76.57 M(-10.2%) |
| Sep 2023 | - | -$17.40 M(-14.2%) | -$85.28 M(-0.4%) |
| Jun 2023 | - | -$20.29 M(-21.5%) | -$85.65 M(-4.4%) |
| Mar 2023 | - | -$25.83 M(+18.7%) | -$89.62 M(+2.1%) |
| Dec 2022 | -$87.81 M(+2.5%) | -$21.77 M(+22.5%) | -$87.81 M(+1.7%) |
| Sep 2022 | - | -$17.77 M(-26.8%) | -$86.32 M(-1.0%) |
| Jun 2022 | - | -$24.26 M(+1.0%) | -$87.22 M(+6.4%) |
| Mar 2022 | - | -$24.02 M(+18.5%) | -$81.98 M(-4.3%) |
| Dec 2021 | -$85.64 M(-20.0%) | -$20.27 M(+8.6%) | -$85.64 M(-1.3%) |
| Sep 2021 | - | -$18.67 M(-1.8%) | -$86.79 M(-7.5%) |
| Jun 2021 | - | -$19.01 M(-31.3%) | -$93.86 M(-5.3%) |
| Mar 2021 | - | -$27.69 M(+29.3%) | -$99.06 M(-7.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2020 | -$107.10 M(+50.1%) | -$21.41 M(-16.8%) | -$107.10 M(-4.3%) |
| Sep 2020 | - | -$25.74 M(+6.3%) | -$111.88 M(+13.3%) |
| Jun 2020 | - | -$24.22 M(-32.2%) | -$98.72 M(+10.8%) |
| Mar 2020 | - | -$35.73 M(+36.4%) | -$89.09 M(+24.9%) |
| Dec 2019 | -$71.34 M(+88.3%) | -$26.19 M(+108.3%) | -$71.34 M(+28.6%) |
| Sep 2019 | - | -$12.58 M(-13.8%) | -$55.46 M(+5.7%) |
| Jun 2019 | - | -$14.60 M(-18.8%) | -$52.49 M(+13.7%) |
| Mar 2019 | - | -$17.98 M(+74.4%) | -$46.18 M(+21.9%) |
| Dec 2018 | -$37.89 M(+285.1%) | -$10.31 M(+7.3%) | -$37.89 M(+12.5%) |
| Sep 2018 | - | -$9.61 M(+16.1%) | -$33.70 M(+56.7%) |
| Jun 2018 | - | -$8.28 M(-14.6%) | -$21.51 M(+28.7%) |
| Mar 2018 | - | -$9.70 M(+58.6%) | -$16.71 M(+69.9%) |
| Dec 2017 | -$9.84 M(-381.6%) | -$6.11 M(-337.2%) | -$9.84 M(+164.0%) |
| Sep 2017 | - | $2.58 M(-174.0%) | -$3.73 M(-40.9%) |
| Jun 2017 | - | -$3.48 M(+23.3%) | -$6.30 M(+123.3%) |
| Mar 2017 | - | -$2.82 M | -$2.82 M |
| Dec 2016 | $3.49 M(-146.7%) | - | - |
| Dec 2015 | -$7.48 M | - | - |
FAQ
- What is UroGen Pharma annual free cash flow?
- What is the all time high annual FCF for UroGen Pharma?
- What is UroGen Pharma annual FCF year-on-year change?
- What is UroGen Pharma quarterly free cash flow?
- What is the all time high quarterly FCF for UroGen Pharma?
- What is UroGen Pharma quarterly FCF year-on-year change?
- What is UroGen Pharma TTM free cash flow?
- What is the all time high TTM FCF for UroGen Pharma?
- What is UroGen Pharma TTM FCF year-on-year change?
What is UroGen Pharma annual free cash flow?
The current annual FCF of URGN is -$97.06 M
What is the all time high annual FCF for UroGen Pharma?
UroGen Pharma all-time high annual free cash flow is $3.49 M
What is UroGen Pharma annual FCF year-on-year change?
Over the past year, URGN annual free cash flow has changed by -$20.49 M (-26.76%)
What is UroGen Pharma quarterly free cash flow?
The current quarterly FCF of URGN is -$13.73 M
What is the all time high quarterly FCF for UroGen Pharma?
UroGen Pharma all-time high quarterly free cash flow is $2.58 M
What is UroGen Pharma quarterly FCF year-on-year change?
Over the past year, URGN quarterly free cash flow has changed by +$14.03 M (+50.53%)
What is UroGen Pharma TTM free cash flow?
The current TTM FCF of URGN is -$97.06 M
What is the all time high TTM FCF for UroGen Pharma?
UroGen Pharma all-time high TTM free cash flow is -$2.82 M
What is UroGen Pharma TTM FCF year-on-year change?
Over the past year, URGN TTM free cash flow has changed by -$682.00 K (-0.71%)